Pipeline

Sorrento's R&D yakatarisana nekutyaira hunyanzvi muCCIDID-19, kurapwa kenza, kudzora marwadzo akazara uye autoimmune zvirwere.

Zvirongwa zvinokosha Chiratidzo Preclinical Phase I Phase II Chikamu III/Chinokosha FDA Chibvumirano
COVID-19 Zvirongwa  

COVISTIX™ (diagnostic) Rapid Antigen Test

*

Emergency Use Authorization (EUA) muMexico (COFEPRIS), Brazil (ANVISA), uye CE Yakanyorwa muEurope.

COVIMARK™ (diagnostic) Rapid Antigen Test

*

Chikumbiro chakatumirwa muUS neCanada cheEmergency Use Authorization (EUA)

VIREX (diagnostic) Kumba Diagnostic

60.2%*

EUA Enabling Studies in Q3 2022

COVISHIELD™ (kurapa) Neutralizing Antibody (IV) muVarwere Vekunze uye Varwere

20%*

FUJOVEE™ (Abivertinib) Yakanyanya COVID-19 muICU Varwere

82%*

Pivotal Muedzo Wakamirira FDA Clearance

OQORY™ (COVI-MSC) ARDS nekuda kweCOVID-19 muICU Varwere

82%*

Muedzo Wakakosha muBrazil

Maifarira Inhibitor (piritsi remuromo) Anti-hutachiona

40%*

Omicron mRNA Vaccine mushonga

20%*

Zvirongwa zvinokosha Chiratidzo Preclinical Phase I Phase II Chikamu III/Chinokosha FDA Chibvumirano
immunotherapy  

FUJOVEE™ (Abivertinib) NSCLC

82%*

FUJOVEE™ (Abivertinib) B Cell Lymphomas

60.2%*

FUJOVEE™ (Abivertinib) Prostate

20%*

FUJOVEE™ (Abivertinib) Lupus

20%*

FUJOVEE™ (Abivertinib) MS

20%*

FUJOVEE™ (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

*Mukubatana naLee's Pharm muChina

PD-L1 (STI-3031)** Cervical Cancer

82%*

** MuUS uye mukubatana neImmuneOncia muKorea

CD47 Solor Tumors

40%*

CD38 DAR-T Multiel Myeloma

40%*

CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, uye esophageal

40%*

Seprehvec™ oncolytic virus Solid Tumors; CNS Tumors

40%*

BCMA ADC Liquid Tumors

20%*

Bevacizumab-ADAB™ Endometrial Cancer

40%*

Mukubatana neMayo Clinic

Bevacizumab-ADAB™ Ovarian Cancer

40%*

Mukubatana neMayo Clinic

Rituximab-ADAB™ B-cell Lymphomas

40%*

Mukubatana neMayo Clinic

Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma

40%*

Zvirongwa zvinokosha Chiratidzo Preclinical Phase I Phase II Chikamu III/Chinokosha FDA Chibvumirano
Pain  

ZTlido® 1.8%
Postherpetic Neuralgia - PHN

99.8%*

Gloperba®
Kurapa Gout (Oral)

99.8%*

SEMEXA (SP-102) Lumbar Radicular / Sciatica Pain

82%*

SP-103 (Lidocaine Topical System 5.4%) Acute Back Kurwadziwa

60.2%*

SP-104 (Yanonoka Kuputika Yakaderera Dose Naltrexone) Fibromyalgia

20%*

RTX (resiniferatoxin)
Epidural injection
Marwadzo Asingagoneki muAdvanced Cancer

60.3%*

Nherera zita

RTX (resiniferatoxin)
Intra-articular nzira
Marwadzo ari pakati nepakati kusvika Pamabvi Akanyanya OA

60.2%*

Zvirongwa zvinokosha Chiratidzo Preclinical Phase I Phase II Chikamu III/Chinokosha FDA Chibvumirano
Lymphatic Drug Delivery  

Sofusa® anti-TNF Autoimmune (RA)

40%*

Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma

40%*

Sofusa® anti-CTLA-4 Melanoma

40%*

Mukubatana neMayo Clinic
COVID-19 Zvirongwa
Zvirongwa zvinokosha (Chiratidzo) Phase
COVISTIX™ (diagnostic) FDA EUA
COVIMARK™ (diagnostic) FDA EUA
VIREX (diagnostic) PH III
COVISHIELD™ (kurapa) PH I
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Maifarira Inhibitor (piritsi remuromo) Ph II
Omicron mRNA Vaccine Preclinical
immunotherapy
Zvirongwa zvinokosha (Chiratidzo) Phase
FUJOVEE™ (Abivertinib) Ph III
FUJOVEE™ (Abivertinib) Ph II
FUJOVEE™ (Abivertinib) Preclinical
FUJOVEE™ (Abivertinib) Preclinical
FUJOVEE™ (Abivertinib) Preclinical
FUJOVEE™ (Abivertinib) Preclinical
PD-L1 (Socazolimab)* Ph III
PD-L1 (STI-3031)** Ph III
CD47 (Mamota Akasimba) Ph I
CD38 DAR-T (Multiple Myeloma) Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, uye esophageal) Ph I
Seprehvec™ oncolytic virus (Mamota Akasimba; CNS Tumors) PH I
BCMA ADC (Liquid Tumors) Preclinical
Bevacizumab-ADAB™ (Endometrial Cancer) Ph I
Bevacizumab-ADAB™ (Ovarian Cancer) Ph I
Rituximab-ADAB™ (B-cell Lymphomas) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
Pain
Zvirongwa zvinokosha (Chiratidzo) Phase
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) FDA Chibvumirano
Gloperba® 1.8% Kurapa Gout (Oral) FDA Chibvumirano
SEMEXA (SP-102) Ph III
SP-103 (Lidocaine Topical System 5.4%) Ph II
SP-104 (Yanonoka Kuputika Yakaderera Dose Naltrexone) Preclinical
RTX (resiniferatoxin) Epidural injection Ph II
RTX (resiniferatoxin) Intra-articular nzira Ph II
Lymphatic Delivery
Zvirongwa zvinokosha (Chiratidzo) Phase II
Sofusa® anti-TNF (Autoimmune RA) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
Sofusa® anti-CTLA-4 (Melanoma) Ph I